Press Releases
March 4, 2026
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
February 12, 2026
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
February 1, 2026
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
December 19, 2025
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
December 12, 2025
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways
November 30, 2025
NurExone Biologic Inc. Announces Third Quarter 2025 Financial Results and Provides Corporate Update
November 18, 2025
The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for “Best Bridge-Builder Institution,” “Best Biomedical Product,” “Best Medical Technology/AI Advances in Human Health,” “Best Product for Rare/Orphan Diseases,” and “Best Public Sector Innovation”
November 12, 2025
NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
November 3, 2025
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
October 21, 2025